small molecule

FRUZAQLA

FRUQUINTINIB

Loss of exclusivitySeptember 2035latest FDA-listed patent expiry

CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand name	FRUZAQLA
Active ingredient	FRUQUINTINIB
Strength	1MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	November 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
11046674	September 2035	use U-3753
10519142	September 2035	substance, product
7829574	March 2032	substance, product
8212033	May 2028	use U-3753

Regulatory exclusivity

Code	Expires
NCE	November 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from TAKEDA PHARMACEUTICALS USA INC